Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

Published by: BioSeeker Group AB

Published: Mar. 17, 2008 - 231 Pages

Table of Contents

Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 How to Use this Report

6 Anti-Angiogenic Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Angiogenesis Drug Targets

7.1 Anti-Angiogenic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Anti-Angiogenic Drug Targets in Human

8.1 Expression in Normal Tissues and Cancer Tissues

8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Anti-Angiogenic Drugs

10 Protein-Protein Interactions Among Identified Anti-Angiogenic Drug Targets

11 Available Biological Structure Data on Anti-Angiogenic Drug Targets

12 Drug Target Profiles of Anti-angiogenesis Drug Targets in Oncology

12.1.1 Carboxy-Lyase Activity

12.1.2 Catalytic Activity

12.1.3 Cell Adhesion Molecule Activity

12.1.4 Chaperone Activity

12.1.5 Cofactor Binding

12.1.6 Cysteine-Type Peptidase Activity

12.1.7 Cytokine Activity

12.1.8 DNA Topoisomerase Activity

12.1.9 DNA-Directed DNA Polymerase Activity

12.1.10 Extracellular Matrix Structural Constituent

12.1.11 G-Protein Coupled Receptor Activity

12.1.12 Growth Factor Activity

12.1.13 GTPase Activity

12.1.14 Hydrolase Activity

12.1.15 Kinase Activity

12.1.16 Lipid Kinase Activity

12.1.17 Metallopeptidase Activity

12.1.18 Molecular Function Unknown

12.1.19 Motor Activity

12.1.20 Peptidase Activity

12.1.21 Protease Inhibitor Activity

12.1.22 Protein Serine/Threonine Kinase Activity

12.1.23 Protein-Tyrosine Kinase Activity

12.1.24 Receptor Activity

12.1.25 Receptor Binding

12.1.26 Serine-Type Peptidase Activity

12.1.27 Structural Constituent of Cytoskeleton

12.1.28 Superoxide Dismutase Activity

12.1.29 Transcription Factor Activity

12.1.30 Transcription Regulator Activity

12.1.31 Translation Regulator Activity

12.1.32 Transmembrane Receptor Activity

12.1.33 Transmembrane Receptor Protein Tyrosine Kinase Activity

12.1.34 Transporter Activity

13 The Drug-Protein Interactome of Anti-Angiogenic Drugs

14 The Progression and Maturity of Anti-Angiogenic Drug Target Combinations

14.1 Target Profiles of Anti-Angiogenic Drugs on the Market

14.2 New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development

14.3 New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development

14.4 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development

14.5 New Anti-Angiogenic Drug Target Combinations in Preclinical Development

14.6 Development Profiles of All Identified Anti-Angiogenic Drug Target Combinations

15 Anti-Angiogenic Drug Target Mix by Cancer Indication

15.1 Adrenal Cancer

15.2 Biliary Cancer

15.3 Bladder Cancer

15.4 Bone Cancer

15.5 Brain Cancer

15.6 Breast Cancer

15.7 Carcinoid Tumor

15.8 Cervical Cancer

15.9 Chemotherapy-Induced Infection

15.10 Colorectal Cancer

15.11 Endometrial Cancer

15.12 Fallopian Tube Cancer

15.13 Gastrointestinal Cancer

15.13.1 Gastrointestinal Stomach Cancer

15.13.2 Gastrointestinal Stromal Cancer

15.14 Head and Neck Cancer

15.15 Leukemia

15.15.1 Acute Lymphocytic Leukemia

15.15.2 Acute Myelogenous Leukemia

15.15.3 Chronic Lymphocytic Leukemia

15.15.4 Chronic Myelogenous Leukemia

15.16 Liver Cancer

15.17 Lung Cancer

15.17.1 Non-Small Cell Lung Cancer

15.17.2 Small Cell Lung Cancer

15.18 Lymphoma

15.18.1 B-Cell Lymphoma

15.18.2 Hodgkin’s Lymphoma

15.18.3 Non-Hodgkin’s Lymphoma

15.19 Melanoma

15.20 Mesothelioma

15.21 Myelodysplastic Syndrome

15.22 Myeloma

15.23 Nasopharyngeal Cancer

15.24 Oesophageal Cancer

15.25 Ovarian Cancer

15.26 Pancreatic Cancer

15.27 Peritoneal Cancer

15.28 Prostate Cancer

15.29 Renal Cancer

15.30 Sarcoma

15.30.1 Leiomyo Sarcoma

15.31 Squamous Cell Cancer

15.32 Thyroid Cancer

16 Anti-Angiogenic Drugs and Their Targets by Companies

16.1 Australia

16.2 Austria

16.3 Belgium

16.4 Canada

16.5 China

16.6 Denmark

16.7 France

16.8 Germany

16.9 Israel

16.10 Japan

16.11 Netherlands

16.12 South Korea

16.13 Spain

16.14 Sweden

16.15 Switzerland

16.16 United Kingdom

16.17 USA

17 Disclaimer

18 Drug Index

19 Company Index

4.1 List of Figures

Figure 1: Distribution of Compound Types Among Anti-Angiogenic Drugs

Figure 2: Primary Sub-cellular Localization of Drug Targets

Figure 3: Visualization of Protein-Protein Interactions Among Anti-Angiogenic Drug Targets

Figure 4: The Drug-Protein Interactome of Anti-Angiogenic Drugs

Figure 5: Direct Head-to-Head Targeting Interactome of Anti-Angiogenic Drugs

4.2 List of Tables

Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target

Table 2: Drug Targets of Anti-Angiogenic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census

Table 3: Available Protein Expression Profiles of Anti-Angiogenic Drug Targets

Table 4: Pathway Summary

Table 5: Drug Targets Without any Identified Assigned Pathways

Table 6: Pathway Profile According to BioCarta of the Anti-Angiogenic Drug Targets

Table 7: Pathway Profile According to KEGG of the Anti-Angiogenic Drug Targets

Table 8: Anti-Angiogenic Drugs Targeting Major Singaling Pathways

Table 9: Protein-Protein Interactions Among Anti-Angiogenic Drug Targets

Table 10: Number of Available Biological Structures on Anti-Angiogenic Drug Targets

Table 11: Overview of Drug Target Profile Themes

Table 12: Drug-Protein Clusters in the Anti-Angiogenic Interactome

Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage

Table 14: Target Profiles of Anti-Angiogenic Drugs on the Market

Table 15: New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development

Table 16: New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development

Table 17 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development

Table 18: New Anti-Angiogenic Drug Target Combinations in Preclinical Development

Table 19: The Progression, Maturity and Comptitive Comparison of Anti-Angiogenic Drug Target Mixes in Development

Table 20: Number of Unique Anti-angiogenic Drug Target Mixes Reported by Cancer Indication

Table 21: The Competitive Situation on Bevacizumab (Avastin)

Table 22: Anti-angiogenic Drug Target Mix for the Treatment of Adrenal Cancer According to the Compound Type and Developmental Stage of Drug

Table 23: Anti-angiogenic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug

Table 24: Anti-angiogenic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug

Table 25: Anti-angiogenic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug

Table 26: Anti-angiogenic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug

Table 27: Anti-angiogenic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug

Table 28: Anti-angiogenic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug

Table 29: Anti-angiogenic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug

Table 30: Anti-angiogenic Drug Target Mix for the Treatment of Chemotherapy-induced Infection According to the Compound Type and Developmental Stage of Drug

Table 31: Anti-angiogenic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug

Table 32: Anti-angiogenic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug

Table 33: Anti-angiogenic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug

Table 34: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Cancer (General) According to the Compound Type and Developmental Stage of Drug

Table 35: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug

Table 36: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug

Table 37: Anti-angiogenic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug

Table 38: Anti-angiogenic Drug Target Mix for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Drug

Table 39: Anti-angiogenic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug

Table 40: Anti-angiogenic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug

Table 41: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia Cancer According to the Compound Type and Developmental Stage of Drug

Table 42: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia Cancer According to the Compound Type and Developmental Stage of Drug

Table 43: Anti-angiogenic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug

Table 44: Anti-angiogenic Drug Target Mix for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Drug

Table 45: Anti-angiogenic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug

Table 46: Anti-angiogenic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug

Table 47: Anti-angiogenic Drug Target Mix for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Drug

Table 48: Anti-angiogenic Drug Target Mix for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 49: Anti-angiogenic Drug Target Mix for the Treatment of Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 50: Anti-angiogenic Drug Target Mix for the Treatment of Non-Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 51: Anti-angiogenic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug

Table 52: Anti-angiogenic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug

Table 53: Anti-angiogenic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug

Table 54: Anti-angiogenic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug

Table 55: Anti-angiogenic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug

Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug

Table 57: Anti-angiogenic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug

Table 58: Anti-angiogenic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug

Table 59: Anti-angiogenic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug

Table 60: Anti-angiogenic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug

Table 61: Anti-angiogenic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug

Table 62: Anti-angiogenic Drug Target Mix for the Treatment of Sarcoma (General) According to the Compound Type and Developmental Stage of Drug

Table 63: Anti-angiogenic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug

Table 64: Anti-angiogenic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug

Table 65: Anti-angiogenic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug

Table 66: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Australia

Table 67: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Austria

Table 68: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Belgium

Table 69: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Canada

Table 70: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in China

Table 71: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Denmark

Table 72: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in France

Table 73; Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Germany

Table 74: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Israel

Table 75: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Japan

Table 76: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in the Netherlands

Table 77: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea .

Table 78: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea .

Table 79: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Sweden

Table 80: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Switzerland

Table 81: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in United Kingdom

Table 82: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in USA

Abstract

• 230+ pages, with almost a hundred different tables and figures. Includes more than 1,500 active links to related resources on the Internet
• 123 anti-angiogenic drugs, under development by 90 investigators, are included, covering more than 361 developmental projects in cancer
• 108 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other anti-angiogenic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
• Unique 231 drug-protein target interactome analysis
• Unique drug target combination breakdown into 44 different cancer types
• Covers 88 unique drug target combinations of anti-angiogenic drugs
• 162 protein-protein interactions among and between anti-angiogenic drug targets
• Pathway grouping of anti-angiogenic drug targets
• Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
• Who are working on sequels to blockbuster drugs
• Locate white-spots in the competitive landscape, giving you little or no competition
• In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.